EP3784265A4 - Modulateurs du récepteur de l'amyline de peptide cyclique thioéther - Google Patents

Modulateurs du récepteur de l'amyline de peptide cyclique thioéther Download PDF

Info

Publication number
EP3784265A4
EP3784265A4 EP19791705.7A EP19791705A EP3784265A4 EP 3784265 A4 EP3784265 A4 EP 3784265A4 EP 19791705 A EP19791705 A EP 19791705A EP 3784265 A4 EP3784265 A4 EP 3784265A4
Authority
EP
European Patent Office
Prior art keywords
cyclic peptide
receptor modulators
amylin receptor
thioether cyclic
peptide amylin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19791705.7A
Other languages
German (de)
English (en)
Other versions
EP3784265A2 (fr
Inventor
Wenying Jian
Raymond Patch
Rui Zhang
Songmao ZHENG
Simon Hinke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP3784265A2 publication Critical patent/EP3784265A2/fr
Publication of EP3784265A4 publication Critical patent/EP3784265A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19791705.7A 2018-04-25 2019-04-17 Modulateurs du récepteur de l'amyline de peptide cyclique thioéther Withdrawn EP3784265A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662492P 2018-04-25 2018-04-25
PCT/IB2019/053194 WO2019207427A2 (fr) 2018-04-25 2019-04-17 Modulateurs du récepteur de l'amyline de peptide cyclique thioéther

Publications (2)

Publication Number Publication Date
EP3784265A2 EP3784265A2 (fr) 2021-03-03
EP3784265A4 true EP3784265A4 (fr) 2022-06-22

Family

ID=68293854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19791705.7A Withdrawn EP3784265A4 (fr) 2018-04-25 2019-04-17 Modulateurs du récepteur de l'amyline de peptide cyclique thioéther

Country Status (5)

Country Link
EP (1) EP3784265A4 (fr)
JP (1) JP2021522231A (fr)
CN (1) CN112074289A (fr)
CA (1) CA3097812A1 (fr)
WO (1) WO2019207427A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN114057862A (zh) * 2021-12-14 2022-02-18 安徽省国平药业有限公司 一种glp-1(1-37)多肽的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050059A1 (fr) * 1997-05-06 1998-11-12 Amylin Pharmaceuticals, Inc. Procedes de prevention de la gastrite au moyen d'amyline ou d'agonistes d'amyline
WO2005115437A2 (fr) * 2004-05-20 2005-12-08 Amylin Pharmaceuticals, Inc. Methodes permettant de modifier la composition du corps
WO2016011208A1 (fr) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Peptides inhibiteurs par voie orale du récepteur de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires de l'intestin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486890B2 (en) * 2006-03-15 2013-07-16 Novo Nordisk A/S Amylin derivatives
EP2036923A1 (fr) * 2007-09-11 2009-03-18 Novo Nordisk A/S Dérivés d'amyline améliorés
CA2764108A1 (fr) * 2009-06-08 2010-12-16 Amunix Operating Inc. Polypeptides de regulation du glucose et leurs procedes de production et d'utilisation
WO2011050008A2 (fr) * 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Polythérapie comprenant l'administration d'un amylinomimétique et d'un peptidomimétique de pyy pour obtenir une perte de poids et pour traiter l'obésité et les états pathologiques et les troubles métaboliques associés
WO2011084808A2 (fr) * 2009-12-21 2011-07-14 Amunix Operating Inc. Compositions de polypeptides bifonctionnels et procédés pour le traitement de maladies métaboliques et cardiovasculaires
CA2837104A1 (fr) * 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Llc Peptides amylines et leurs derives et utilisations
US20140249076A1 (en) * 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
WO2017075522A2 (fr) * 2015-10-28 2017-05-04 Tufts University Polypeptides glp-2 présentant une meilleure stabilité protéolytique et leurs procédés de préparation et d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050059A1 (fr) * 1997-05-06 1998-11-12 Amylin Pharmaceuticals, Inc. Procedes de prevention de la gastrite au moyen d'amyline ou d'agonistes d'amyline
WO2005115437A2 (fr) * 2004-05-20 2005-12-08 Amylin Pharmaceuticals, Inc. Methodes permettant de modifier la composition du corps
WO2016011208A1 (fr) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Peptides inhibiteurs par voie orale du récepteur de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires de l'intestin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLL G N ET AL: "A biological stabilization technology for peptide drugs: enzymatic introduction of thioether-bridges", DRUG DISCOVERY TODAY: TECHNOLOGIES, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 1-4, January 2009 (2009-01-01), pages e13 - e18, XP027503974, ISSN: 1740-6749, [retrieved on 20090419], DOI: 10.1016/J.DDTEC.2009.03.001 *

Also Published As

Publication number Publication date
EP3784265A2 (fr) 2021-03-03
JP2021522231A (ja) 2021-08-30
WO2019207427A3 (fr) 2020-01-02
CN112074289A (zh) 2020-12-11
WO2019207427A2 (fr) 2019-10-31
CA3097812A1 (fr) 2019-10-31

Similar Documents

Publication Publication Date Title
EP3787302A4 (fr) Système d'amélioration de résolution fondé sur l'intelligence artificielle
EP3802852A4 (fr) Peptide cyclique modifié
EP3723783A4 (fr) Peptides ciblant les mitochondries
EP3893913A4 (fr) Peptides ciblant un récepteur de la transferrine
LT3743406T (lt) Tmem16a modulatoriai
EP3580223A4 (fr) Modulateurs du récepteur des strogènes de benzothiophène
EP3645031A4 (fr) Analogues peptidiques
GB2576056B (en) Modulators
EP3790890A4 (fr) Peptides cycliques de pénétration cellulaire avec un ou plusieurs résidus hydrophobes
EP3724220A4 (fr) Récepteurs daric nkg2d
EP3700558A4 (fr) Constructions immunogènes de peptide tau
IL280678A (en) Cell-penetrating peptides
EP3768297A4 (fr) Analogues de tétrapeptides cycliques
GB2585803B (en) Electro-absorption modulator
EP3784265A4 (fr) Modulateurs du récepteur de l'amyline de peptide cyclique thioéther
EP3802565A4 (fr) Polypeptides
EP3802123A4 (fr) Membrane d'imperméabilisation à l'eau résistant à la gueule de poisson
AU2019350356A1 (en) Arginase1 polypeptides
EP3765020A4 (fr) Modulateurs de ror-gamma spirocycliques
EP3583090A4 (fr) Modulateurs du récepteur ff de neuropeptide à base de proline
EP3581572B8 (fr) Modulateurs des récepteurs a3 de l'adénosine
IL284006A (en) Mitochondria-targeted peptides
EP3851448A4 (fr) Peptide récepteur anti-érythropoïétine
EP3792349A4 (fr) Macrocyclase peptidique
EP3681875A4 (fr) Antibiotiques peptidiques cycliques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201123

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220520

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/72 20060101ALI20220516BHEP

Ipc: C07K 14/47 20060101ALI20220516BHEP

Ipc: A61P 3/10 20060101ALI20220516BHEP

Ipc: A61P 1/16 20060101ALI20220516BHEP

Ipc: A61K 38/17 20060101AFI20220516BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221220